Figure 7.
JAK inhibition blocks tumor cell–induced reduction of filaggrin and FLG2 in keratinocytes and in ex vivo MF skin. (A) RHE samples were cultured for 24 hours with the malignant MF2059 T-cell line in the presence of either 1 μM JAK inhibitor (tofacitinib) or dimethyl sulfoxide (DMSO) (control). (B) RHE samples were cultured in the presence of supernatants for 48 hours with 1 μM tofacitinib or DMSO. (C) Skin biopsies from MF plaques were cultured with 1 μM tofacitinib or DMSO for 72 hours. mRNA expression was analyzed by qPCR using β-actin as a reference gene in panels A and C. Gene expression was given as relative expression. Protein expression was analyzed by IHC for RHE samples. The RHE samples were stained for H&E, filaggrin, and filaggrin-2. Images are scanned by the Zeiss Axio Scan.Z1 with original magnification ×20. Scale bar; 50 μm. n = 3, ∗P < .05.

JAK inhibition blocks tumor cell–induced reduction of filaggrin and FLG2 in keratinocytes and in ex vivo MF skin. (A) RHE samples were cultured for 24 hours with the malignant MF2059 T-cell line in the presence of either 1 μM JAK inhibitor (tofacitinib) or dimethyl sulfoxide (DMSO) (control). (B) RHE samples were cultured in the presence of supernatants for 48 hours with 1 μM tofacitinib or DMSO. (C) Skin biopsies from MF plaques were cultured with 1 μM tofacitinib or DMSO for 72 hours. mRNA expression was analyzed by qPCR using β-actin as a reference gene in panels A and C. Gene expression was given as relative expression. Protein expression was analyzed by IHC for RHE samples. The RHE samples were stained for H&E, filaggrin, and filaggrin-2. Images are scanned by the Zeiss Axio Scan.Z1 with original magnification ×20. Scale bar; 50 μm. n = 3, ∗P < .05.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal